image
Ardelyx, Inc. ARDX
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 4.27
1.91 %
$ 1.02 B
Market Cap
-18.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ARDX stock under the worst case scenario is HIDDEN Compared to the current market price of 4.27 USD, Ardelyx, Inc. is HIDDEN

ARDX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ARDX stock under the base case scenario is HIDDEN Compared to the current market price of 4.27 USD, Ardelyx, Inc. is HIDDEN

ARDX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ARDX stock under the best case scenario is HIDDEN Compared to the current market price of 4.27 USD, Ardelyx, Inc. is HIDDEN

ARDX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ARDX

image
1M 20%
6M -21%
1Y -29.0%
3Y 514%
5Y 153%
All
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
334 M REVENUE
168.06%
Growth Rates
1Year 168.06%
3Years 220.89%
5Years 129.14%
7Years 34.45%
10Years 26.57%
-28 M OPERATING INCOME
55.83%
Growth Rates
1Year 55.83%
3Years 43.42%
5Years 21.07%
7Years 11.38%
10Years -33.42%
-39.1 M NET INCOME
40.76%
Growth Rates
1Year 40.76%
3Years 37.22%
5Years 16.24%
7Years 6.86%
10Years -28.40%
-44.8 M OPERATING CASH FLOW
50.06%
Growth Rates
1Year 50.06%
3Years 33.53%
5Years 10.14%
7Years 5.21%
10Years -15.82%
-18.3 M INVESTING CASH FLOW
86.04%
Growth Rates
1Year 86.04%
3Years -10.78%
5Years -12.27%
7Years -3.60%
10Years -25.73%
107 M FINANCING CASH FLOW
-27.14%
Growth Rates
1Year -27.14%
3Years 8.70%
5Years -7.27%
7Years 105.66%
10Years 5.69%
74.1 M REVENUE
-36.18%
Growth Rates
1Year 168.06%
3Years 220.89%
5Years 129.14%
7Years 34.45%
10Years 26.57%
-36.3 M OPERATING INCOME
-447.37%
Growth Rates
1Year 55.83%
3Years 43.42%
5Years 21.07%
7Years 11.38%
10Years -33.42%
-41.1 M NET INCOME
-885.77%
Growth Rates
1Year 40.76%
3Years 37.22%
5Years 16.24%
7Years 6.86%
10Years -28.40%
-38.5 M OPERATING CASH FLOW
-392.02%
Growth Rates
1Year 50.06%
3Years 33.53%
5Years 10.14%
7Years 5.21%
10Years -15.82%
2.85 M INVESTING CASH FLOW
106.85%
Growth Rates
1Year 86.04%
3Years -10.78%
5Years -12.27%
7Years -3.60%
10Years -25.73%
1.48 M FINANCING CASH FLOW
-96.99%
Growth Rates
1Year -27.14%
3Years 8.70%
5Years -7.27%
7Years 105.66%
10Years 5.69%
Balance Sheet Ardelyx, Inc.
image
Current Assets 356 M
Cash & Short-Term Investments 250 M
Receivables 57.7 M
Other Current Assets 48.6 M
Non-Current Assets 79.3 M
Long-Term Investments 0
PP&E 3.88 M
Other Non-Current Assets 75.4 M
57.39 %13.24 %11.16 %17.31 %Total Assets$435.8m
Current Liabilities 77.8 M
Accounts Payable 16 M
Short-Term Debt 1.56 M
Other Current Liabilities 60.3 M
Non-Current Liabilities 185 M
Long-Term Debt 152 M
Other Non-Current Liabilities 32.8 M
6.10 %22.96 %57.87 %12.48 %Total Liabilities$262.5m
EFFICIENCY
Earnings Waterfall Ardelyx, Inc.
image
Revenue 334 M
Cost Of Revenue 50.6 M
Gross Profit 283 M
Operating Expenses 311 M
Operating Income -28 M
Other Expenses 11.2 M
Net Income -39.1 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)334m(51m)283m(311m)(28m)(11m)(39m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.85% GROSS MARGIN
84.85%
Averages
1Year 84.85%
3Years 87.55%
5Years 90.17%
7Years 88.80%
10Years 89.28%
-8.38% OPERATING MARGIN
-8.38%
Averages
1Year -8.38%
3Years -60.49%
5Years -581.83%
7Years -1160.84%
10Years -887.31%
-11.73% NET MARGIN
-11.73%
Averages
1Year -11.73%
3Years -64.56%
5Years -601.17%
7Years -1186.52%
10Years -904.99%
-22.58% ROE
-22.58%
Averages
1Year -22.58%
3Years -43.51%
5Years -79.35%
7Years -75.21%
10Years -65.80%
-8.98% ROA
-8.98%
Averages
1Year -8.98%
3Years -22.18%
5Years -43.77%
7Years -43.60%
10Years -42.40%
-7.83% ROIC
-7.83%
Averages
1Year -7.83%
3Years -25.24%
5Years -48.60%
7Years -47.92%
10Years -46.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ardelyx, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -39.1 M
Depreciation & Amortization 2.06 M
Capital Expenditures -1.01 M
Stock-Based Compensation 37.4 M
Change in Working Capital -49.2 M
Others 27.4 M
Free Cash Flow -45.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ardelyx, Inc.
image
Wall Street analysts predict an average 1-year price target for ARDX of $11 , with forecasts ranging from a low of $8 to a high of $14 .
ARDX Lowest Price Target Wall Street Target
8 USD 87.35%
ARDX Average Price Target Wall Street Target
11 USD 157.61%
ARDX Highest Price Target Wall Street Target
14 USD 227.87%
Price
Max Price Target
Min Price Target
Average Price Target
14141212101088664422Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Ardelyx, Inc.
image
Sold
0-3 MONTHS
518 K USD 6
3-6 MONTHS
848 K USD 4
6-9 MONTHS
1.28 M USD 6
9-12 MONTHS
1.54 M USD 7
Bought
3.4 M USD 1
0-3 MONTHS
1.38 M USD 1
3-6 MONTHS
1.99 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
8. Profile Summary

Ardelyx, Inc. ARDX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.02 B
Dividend Yield 0.00%
Description Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Contact 400 Fifth Avenue, Waltham, MA, 02451 https://www.ardelyx.com
IPO Date June 19, 2014
Employees 395
Officers Mr. Michael G. Raab President, Chief Executive Officer & Director Dr. Laura A. Williams M.D., M.P.H. Chief Patient Officer Ms. Elizabeth A. Grammer Esq. Chief Legal & Administrative Officer and Secretary Ms. Caitlin Lowie Vice President of Corporate Communications & Investor Relations Mr. Mike Kelliher Executive Vice President of Corporate Development & Strategy Mr. David P. Rosenbaum Ph.D. Head of Drug Discovery and Early Development Mr. Eric Duane Foster Chief Commercial Officer Mr. Justin A. Renz CPA, MBA Chief Financial & Operations Officer Mr. Joseph Reilly Senior Vice President of Finance & Principal Accounting Officer